Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06265285 | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | recruiting | Phase 2 | 50 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2(SPRINT 2) | not yet recruiting | Phase 2 | 52 | Montefiore Medical CenterOTHER | 1 | Jun 9, 2026 |
| clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07637448 | EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC | recruiting | Phase 2 | 32 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 218 | NRG OncologyOTHER | 4 | Jun 8, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | active not recruiting | Phase 2 | 45 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04258033 | A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)(KUNPENG) | completed | Phase 2 | 145 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04334941 | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | active not recruiting | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab | terminated | Phase 1 / Phase 2 | 6 | University of NebraskaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07485452 | Boosting Osimertinib Blood Brain Barrier Penetration(OSIBBBOOST) | recruiting | Phase 2 | 7 | Maastricht University Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630077 | Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | recruiting | Phase 1 / Phase 2 | 41 | OSE ImmunotherapeuticsINDUSTRY | 3 | Jun 4, 2026 | clinicaltrials |
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jun 4, 2026 | clinicaltrials |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | recruiting | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer(PRAD2) | not yet recruiting | Phase 2 | 39 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT05642572 | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | recruiting | Phase 2 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622706 | Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT06731413 | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 40 | Virginia Commonwealth UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619911 | SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 84 | Fudan UniversityOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | active not recruiting | Phase 1 / Phase 2 | 110 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Jun 1, 2026 | clinicaltrials |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer(VELOCITY-Lung) | active not recruiting | Phase 2 | 192 | Gilead SciencesINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer(EDGE-Lung) | active not recruiting | Phase 2 | 400 | Gilead SciencesINDUSTRY | 10 | Jun 1, 2026 | clinicaltrials |
| NCT05933239 | Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients(MAGMA) | recruiting | Phase 2 | 20 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)(LUNAR-4) | terminated | Phase 2 | 31 | NovoCure GmbHINDUSTRY | 7 | Jun 1, 2026 | clinicaltrials |
| NCT07618793 | Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | zhang yiOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | active not recruiting | Phase 2 | 70 | Eikon TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） | not yet recruiting | Phase 2 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06974370 | Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial(ACTION-Brain) | recruiting | Phase 2 | 45 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07249372 | DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | recruiting | Phase 2 | 37 | NYU Langone HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07375316 | A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | recruiting | Phase 2 | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | active not recruiting | Phase 2 | 36 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2026source: clinicaltrials